“We are making progress on our other oral long-acting candidates and continue to expect our wholly owned once-weekly program to be moving forward with a delay of 3 to 6 quarters.”

In context

“In HIV treatment, we continue to expect an update on our new daily oral combination of bictegravir and lenacapavir in the second half of the year from ARTISTRY-1 in people with HIV on complex regimens. In addition to ARTISTRY-1, we now expect to provide an update for ARTISTRY-2, the second Phase III trial for BIC/LEN for virally suppressed people with HIV or people looking to switch regimens. Looking at our weekly HIV treatment programs, we expect the Phase III update on the lenacapavir plus islatravir combination in 2026 with a view to potential launch in 2027. As we announced, our wholly owned weekly WONDERS program evaluating the combination of GS-4182, one of our lenacapavir prodrugs and GS-1720, one of our long-acting integrase inhibitors is on clinical hold pending further analysis. We are making progress on our other oral long-acting candidates and continue to expect our wholly owned once-weekly program to be moving forward with a delay of 3 to 6 quarters. Among the rest of our leading HIV programs, three are in Phase I, namely our monthly oral and our quarterly and twice yearly injectables. We look forward to sharing updates on these in due course. Finally, we continue to plan for our Phase III study evaluating lenacapavir plus broadly neutralizing antibodies or bNAbs as a potential twice yearly injectable treatment. We continue to target commercial launch in 2030. Moving to oncology on Slide 18. Trodelvy's impact in metastatic triple-negative breast cancer was reinforced with highly statistically significant and clinically meaningful results in the Phase III ASCENT-03 and ASCENT-04 studies in the first-line setting. At ASCO, we presented potentially practice-changing detailed data from ASCENT-04, showing treatment with Trodelvy plus pembr”